Article info

Download PDFPDF

Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol

Authors

  1. Correspondence to Anette-Gabriele Ziegler; anette-g.ziegler{at}helmholtz-muenchen.de
View Full Text

Citation

Ziegler A, Achenbach P, Berner R and the GPPAD Study group, et al
Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol

Publication history

  • Received December 21, 2018
  • Revised April 18, 2019
  • Accepted May 21, 2019
  • First published June 28, 2019.
Online issue publication 
June 28, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.